Pharmaceutical companies—including Eli Lilly and Novo Nordisk, which currently dominate the obesity market—have been testing pills that could help people lose weight. On Thursday, Eli Lilly’s daily pill called orforglipron met its goals in a trial,

The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve improved blood sugar control and weight loss.

The S&P 500 rose on Thursday, lifted by Eli Lilly and Apple, as investors weighed progress in U.S. trade negotiations with Japan against concerns about the outlook for interest rates. Traders leaned toward optimism following U.